M. Docteur NICOLAS SEGAUD

Bibliographie

• Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison

  2021

  ArticleRheumatology

• Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study

  2019

  ArticleRheumatology and Therapy

• Similar Effectiveness of Both Formulations of Tocilizumab (TCZ) in Patients with Rheumatoid Arthritis (RA) Switching from Intravenous (IV) to Subcutaneous (SC) at 6 Months in Real Life

  2017

  ArticleArthritis & rheumatology

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Livres & ouvrages

• 📕

  Evolution de la densité minérale osseuse chez les patients transplantés rénaux

  20140

Source : Google Books — filtre catégories médicales/santé/sciences.

Localisation

Adresses géocodées via la Base Adresse Nationale (api-adresse.data.gouv.fr). Précision indicative.

Lieu de consultation

• CABINET DU DR NICOLAS SEGAUD

  38BIS RUE DE COURLANCY, 51100 Reims

  Libéral
  145 m148 m154 m156 m

  © OpenStreetMap · Photos Wikimedia Commons (CC)

  📷 Street View ↗🗺️ Maps ↗OSM ↗

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

• 1

  Evaluating the safety and short-term equivalence of colchicine versus prednisone in older patients with acute calcium pyrophosphate crystal arthritis (COLCHICORT): an open-label, multicentre, randomised trial

  The Lancet. Rheumatology · 2023

  📚 25 citations🎯 RCR 4.76Top 8% NIH🩺 Clinique
• 2

  Changes in bone mineral density after kidney transplantation: 2-year assessment of a French cohort

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2018

  📚 24 citations🎯 RCR 1.74
• 3

  Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison

  Rheumatology (Oxford, England) · 2021

  📚 12 citations🔓 Open Access📄 PDF gratuit ↗

  Lire l'abstract Crossref ↓

  Abstract Objectives To evaluate the characteristics of patients (pts) with PsA treated by ustekinumab (UST) or secukinumab (SEK) and to compare real-world persistence of UST and SEK in PsA. Methods In this retrospective, national, multicentre cohort study, pts with PsA (CASPAR criteria or diagnosis confirmed by the rheumatologist) initiating UST or SEK with a follow-up ≥6 months were included from January 2011 to April 2019. The persistence between SEK and UST was assessed after considering the potential confounding factors by using pre-specified propensity-score methods. Causes of discontinuation and tolerance were also collected. Results A total of 406 pts were included: 245 with UST and 161 with SEK. The persistence rate was lower in the UST group compared with the SEK group [median persistence 9.4 vs 14.7 months; 26.4% vs 38.0% at 2 years; weighted hazard ratio (HR) = 1.42; 95% CI: 1.07, 1.92; P =0.015]. In subgroup analysis, the persistence rate of SEK associated with MTX was significantly higher than that of UST associated with MTX: HR = 2.20; 95% CI: 1.30, 3.51; P =0.001, in contrast to SEK vs UST monotherapy: HR = 1.06; 95% CI: 0.74, 1.53; P =0.75. Discontinuation due to inefficacy was reported in 91.7% (SEK) and 82.4% (UST) of pts. Discontinuation due to an adverse event was reported in 12.2% (SEK) and 7.7% (UST) of pts. Conclusion In this first study comparing UST and SEK, the persistence of SEK was higher than that of UST in PsA. In subgroup analysis, this difference was only found in association with MTX.

Publications scientifiques (4) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Datasets & protocoles partagés

• Tocilizumab Effectiveness after Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis - The RoSwitch Study

  Image2019Adis Journals

  Full copyright for enhanced digital features is owned by the authors. <strong>Article full text</strong> <br> The full text of this article can be found <b>here</b>. <br> <br> <strong>Provide enhanced digital features fo

• Tocilizumab Effectiveness after Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis - The RoSwitch Study

  Image2019Adis Journals

  Full copyright for enhanced digital features is owned by the authors. <strong>Article full text</strong> <br> The full text of this article can be found <b>here</b>. <br> <br> <strong>Provide enhanced digital features fo

Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).

Partager cette fiche